|View printer-friendly version|
|October 23, 2007 2:11 p.m.|
|Copaxone® Significantly Decreases Disease Activity In Patients Who Switched From Interferon Beta (Ifnb) Due To Development Of Neutralizing Antibodies (Nabs)|
Relapsing-remitting multiple sclerosis Patients Experience Significantly Extended Time to First Relapse Compared to NAbs-Positive IFNb Patients
Jerusalem, Israel, October 23, 2007 - Patients treated with interferon beta (IFNb) who have experienced loss of efficacy due to the development of neutralizing antibodies, had a significant delay in time to first relapse (p=0.0389) following switch to COPAXONE®. In addition, patients who were switched to COPAXONE® experienced reduction in mean annual relapse rate compared to Pre IFNb treatment. Results from this retrospective comparative study were presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague.